'LEQEMBI® Intravenous Infusion' approved for the treatm

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab)...

Related Keywords

Japan , China , Australia , Uppsala , Uppsala Lan , Sweden , Stockholm , Switzerland , United Kingdom , Israel , Canada , South Korea , Swedish , Great Britain , Japanese , Oskar Bosson , Gunilla Osswald , Jiang Millington , Uppsala University , National Institute On , National Institutes Of Health , Drug Administration , Washington University School Of Medicine , Vp Communications , Alzheimer Clinical Trial Consortium , Ad Cooperative Study , Japanese Ministry Of Health , Alzheimer Network Trials Unit , Nasdaq Stockholm , Clinical Dementia Rating Sum , Daily Living Scale , Mild Cognitive Impairment , Clinical Trials , New England Journal , Japanese Ministry , Biogen Japan , Marketing Authorization , Director Corporate Communication , Dose Management , Antithrombotic Medication , Risk Factors , Intracerebral Hemorrhage , Intravenous Infusion , Innovative Licensing , Access Pathway , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Bioarctic ,